Molina Healthcare, Inc. generated $46.8 billion in consolidated premium and service revenues for the fiscal year 2024, operating as a dominant national managed care entity that has aggressively restructured its portfolio through strategic partnerships and internal development to secure next-generation managed care IT and specialty member service assets. The organization employs approximately 11,000 people globally and allocates roughly $500 million annually to research and development, representing a substantial portion of its total sales and underscoring a relentless dedication to pipeline innovation in managed care technology, specialty member services, and advanced data analytics.
Molina Healthcare, Inc.: Key Facts
- Founded: 1980 by C. David Molina in Long Beach, California.
- Headquarters: Long Beach, California.
- CEO: Joe Zubretsky (since 2019).
- FY2024 Revenue: $46.8 billion.
- Employees: Approximately 11,000 people globally.
- Primary Business: Medicaid Management & Retail Support (87% of sales), with a dominant market position in US Medicaid management and medical claims clearinghouse services.
How Does Molina Healthcare Make Money?
The organization generates revenue primarily through its Medicaid Management & Retail Support division, which accounts for the vast majority of sales by selling high-margin biologics, monoclonal antibodies, and targeted therapies like the Change Healthcare platform, specialty pharmacy hub services, and the Medicaid management franchise. The business model is characterized by exceptional gross margins, particularly in the technology segment where margins exceed 50%, providing the cash flow necessary to fund a massive $500 million annual R&D budget and sustain a continuous pipeline of next-generation therapeutic assets. The organization also utilizes a highly specialized sales force to drive adoption of its specialty therapies among managed care IT directors and specialty pharmacists, ensuring that the complex clinical data supporting its targeted technologies is effectively communicated to the medical community. The primary revenue drivers within the portfolio are concentrated in US Medicaid Management, anchored by the management of branded specialty drugs and high-volume generics, which generated approximately $28.0 billion in FY2024, and the medical-surgical distribution franchise led by the supply of PPE, surgical instruments, and laboratory equipment to hospitals and alternative care sites, which contributed approximately $30 billion combined. The Prescription Technology Solutions segment represents the next largest and most rapidly growing therapeutic cluster, driven by the massive commercial success of the Change Healthcare clearinghouse, RelayHealth pharmacy connectivity, and the newly integrated assets from internal technology development and strategic acquisitions. The financial flow of the organization is heavily skewed toward working capital optimization; in FY2024, the organization allocated approximately $2.5 billion to free cash flow generation, representing a substantial portion of its adjusted net income, while simultaneously dedicating significant cash flow to fund the $13.8 billion acquisition of Change Healthcare and service the ongoing obligations of the opioid litigation settlement. This capital structure requires a disciplined approach to cost management and operational efficiency, ensuring that the organization can maintain its R&D investments and shareholder returns while navigating the challenges of a highly leveraged balance sheet. The operating margin for the group sits at a robust level, reflecting the high marginal profitability of its technology portfolio and the economies of scale achieved through its national distribution and commercial infrastructure. The capital allocation strategy prioritizes a strong dividend, distributing over $1.0 billion to shareholders in FY2024, alongside a massive share repurchase program that returned over $4.0 billion to investors, ensuring that despite the massive acquisition spend and litigation obligations, the organization remains a cornerstone holding for value-focused institutional investors. The business model's resilience is tested by the inherent risk of the retail pharmacy consolidation, which is currently manifesting in the severe erosion of traditional community pharmacy footprints and the declining revenue of independent drug stores. The retail pharmacy consolidation represents a multi-billion dollar revenue risk, as the Medicaid management market is highly competitive and the closure of thousands of retail locations will inevitably lead to significant volume loss and market share reallocation to mail-order and specialty channels. To mitigate this, the organization has executed a highly aggressive business development strategy, securing the rights to Change Healthcare for revenue cycle management, a technology platform that has the potential to become a blockbuster asset in the managed care IT space, and expanding its specialty distribution portfolio with the internal development of advanced cold-chain logistics and member adherence programs. The integration of real-world evidence (RWE) through advanced data analytics allows the organization to negotiate value-based pricing contracts with payers, tying the reimbursement of its high-cost specialty therapies to actual member outcomes in clinical practice, a sophisticated pricing mechanism that protects margins in an era of increasing healthcare cost scrutiny. The synergy between the Medicaid management and digital technology divisions is the ultimate moat: a competitor can develop a better claims clearinghouse, or a better specialty logistics network, but replicating the massive national distribution infrastructure, the deep payer relationships, and the technological expertise required to successfully launch and scale these complex assets requires decades of accumulated experience and billions of dollars in investment. If the Medicaid Management division were to disappear, the organization would be reduced to a technology-only entity, lacking the massive cash flows required to fund the billion-dollar cost of acquiring and integrating new managed care IT platforms and the commercial infrastructure to deliver them to providers. Conversely, if the Prescription Technology Solutions division were removed, the organization would lose its primary mechanism for margin expansion, forcing it to compete solely on the physical movement of commodities, a strategy that is ultimately unsustainable in the face of inevitable retail consolidation and generic price deflation. The model is fundamentally designed to convert physical logistics into recurring, high-margin digital revenue streams, utilizing the regulatory barriers to entry in healthcare data privacy and the commercial barriers to entry in provider software integration to maintain pricing power and protect market share against low-cost technology competitors. The distribution footprint is a critical component of this model; the organization operates massive automated distribution centers in the United States, Canada, and Europe, capable of processing millions of lines of pharmaceuticals and medical-surgical supplies daily. This scale creates significant economies of scale, driving down the cost of goods sold (COGS) and allowing it to maintain those exceptional working capital metrics even as pricing pressures mount in key markets. The supply chain for its specialty pharmaceutical pipeline is particularly complex, requiring the production and distribution of biologic molecules with stringent temperature control requirements, a logistical feat that creates significant barriers to entry for potential competitors. The ability to vertically integrate its supply chain, from the raw materials used in its medical-surgical manufacturing to the final delivery of its biologic products to specialty pharmacies and hospital systems, provides a level of operational resilience that is rare in the national healthcare industry. This vertical integration also allows the organization to rapidly scale distribution of new therapies in response to emerging clinical needs, as demonstrated during the national health crises when it rapidly scaled its distribution capacity to support national health initiatives. The financial model is further supported by a sophisticated tax strategy that optimizes the national effective tax rate, allowing the organization to retain a larger portion of its operating income for reinvestment into technology development and shareholder returns. The intellectual property portfolio is one of the most extensive in the managed care technology industry, comprising thousands of patents and copyrights covering everything from the core algorithms of its claims clearinghouse to the specific workflow methodologies used in its pharmacy management software. This extensive intellectual property portfolio provides a critical layer of protection for its technology franchises, extending the period of market exclusivity and delaying the entry of low-cost software competitors. The intellectual property strategy also includes the aggressive pursuit of secondary patents, such as patents covering specific data integrations, user interface designs, and machine learning models, which can provide additional years of market protection even after the core software patents have expired. The R&D model is highly decentralized, with technology development centers located in key biotechnology and software hubs around the world, including Atlanta, Georgia; Nashville, Tennessee; and Waterloo, Canada. This decentralized model allows the organization to tap into the best engineering talent and the most innovative software ecosystems, ensuring that it remains at the forefront of managed care IT discovery. The R&D spending is heavily weighted toward late-stage product development, with a significant portion of its budget allocated to commercializing and integrating its most promising technology assets. This focus on late-stage development reflects the organization's risk-averse approach to software development, preferring to invest heavily in assets that have already demonstrated proof-of-concept in early-stage pilot programs rather than taking on the high risk of early-stage algorithmic research. However, the organization also maintains a robust early-stage research pipeline, supported by its corporate venture capital fund, which invests in promising managed care IT startups and academic spin-outs. This venture capital strategy allows the organization to gain early access to innovative technologies and platforms, providing it with a pipeline of potential acquisition targets and licensing opportunities. The business model is fundamentally designed to generate sustainable, long-term value for its shareholders by combining the high-growth potential of its newly acquired technology assets with the stable, recurring cash flows of its mature Medicaid management franchises. This dual-model structure provides a unique competitive advantage that allows the organization to navigate the inherent volatility of the healthcare industry and deliver consistent financial performance over the long term. The ability to generate significant free cash flow, even in the face of retail consolidation and pricing pressures, provides it with the financial flexibility to pursue strategic acquisitions, invest in new technologies, and return capital to shareholders through dividends and share buybacks. The dedication to innovation is reflected in its continuous investment in managed care technology, its strategic acquisitions of innovative software companies, and its partnerships with academic institutions and research organizations around the world. This dedication to innovation is essential for the long-term success of the enterprise, as it allows the organization to continuously replace expiring revenue with new, high-growth assets and maintain its position as a leader in the national managed care and technology industry. The business model is also characterized by a strong focus on operational excellence, with a continuous effort to improve efficiency, reduce costs, and optimize its national supply chain. This focus on operational excellence is essential for maintaining the competitive advantage and delivering value to its customers and shareholders. The national footprint, with operations in 21 states, provides it with a diverse revenue base and a deep understanding of the local healthcare markets in which it operates. This local expertise allows the organization to tailor its products and services to the specific needs of each market, ensuring that it can effectively compete in a highly diverse and complex national healthcare landscape. The business model is a demonstration of its ability to adapt to the changing needs of the healthcare industry, from the early days of physical drug wholesale to the current era of precision medicine, digital health, and value-based care. This ability to adapt and innovate has been the key to the success of the enterprise over the past two centuries, and it will continue to be essential for its success in the future. The dual-model structure of its Medicaid management and digital technology operations, its extensive intellectual property portfolio, its national distribution footprint, and its dedication to innovation provide it with a unique competitive advantage that will allow it to continue to deliver value to its customers and shareholders for many years to come. The business model is not just a framework for generating revenue; it is a comprehensive strategy for creating sustainable, long-term value for all of its stakeholders, including its patients, its employees, its shareholders, and the communities in which it operates. This dedication to creating value for all stakeholders is the foundation of the corporate culture and the driving force behind its continued success in the national managed care and technology industry. The ability to balance the need for financial performance with its dedication to social responsibility and environmental sustainability is a key differentiator in the healthcare industry, and it is a critical factor in its ability to attract and retain the best talent and the most loyal customers. The business model is a complex, highly integrated system that requires careful management and continuous optimization to ensure its long-term success. The leadership team is deeply dedicated to this continuous optimization, constantly evaluating its strategic priorities, its operational processes, and its capital allocation decisions to ensure that the organization is best positioned to capitalize on the opportunities and navigate the challenges of the national managed care industry. The business model is a key source of its competitive advantage, and it is a critical factor in its ability to deliver consistent financial performance and create sustainable, long-term value for its shareholders. The strategic deployment of capital into the managed care technology franchise, particularly through the full acquisition of Change Healthcare, represents a highly calculated bet on the future of the healthcare revenue cycle, moving away from pure Medicaid management toward a digitally integrated ecosystem that addresses the profound unmet needs of healthcare providers struggling with administrative burden and claim denials. The clinical and operational data supporting the Change Healthcare acquisition demonstrated significant strategic value in consolidating the medical claims clearinghouse market, while maintaining a favorable regulatory profile, particularly regarding the absence of severe antitrust concerns that have historically limited the utility of horizontal consolidation in the managed care technology space. This strategic breakthrough has the potential to capture a significant share of the managed care IT market, providing a much-needed new mechanism of action for a provider population that has seen limited innovation in revenue cycle management over the past thirty years. The commercialization strategy for the Change Healthcare platform involves a highly specialized sales force deployment, targeting hospital chief financial officers and medical group practice administrators that manage the most complex and treatment-resistant revenue cycle challenges, ensuring that the operational benefits of the technology are effectively communicated to the key decision-makers in the healthcare finance space. The pricing and reimbursement strategy for the technology solutions is structured to reflect its significant operational advantage over legacy clearinghouse systems, utilizing health economics and outcomes research data to demonstrate the long-term cost savings associated with reduced claim denials and improved cash flow for providers. The integration of the Change Healthcare platform into the broader organizational structure has been executed with remarkable efficiency, utilizing the existing commercial infrastructure and regulatory expertise to accelerate the development and launch of new technology modules while maintaining the scientific autonomy and innovative culture that made Change Healthcare a premier managed care IT research organization. The strategic focus on specialty pharmaceutical distribution further expands the managed care services franchise, adding a highly promising portfolio of hub services, member adherence programs, and cold-chain logistics solutions that target the complex administration requirements of biologics and cell therapies, a modality that has the potential to transform the treatment landscape for rare diseases and oncology. The specialty pathway has been considered highly complex for over two decades, and the development of comprehensive, end-to-end member support services represents a major operational breakthrough that has the potential to redefine the standard of care for millions of patients. The integration of the specialty distribution assets into the managed care services pipeline provides the organization with a robust platform for next-generation member support, complementing its existing portfolio of Medicaid management and technology solutions. The commercial strategy for the specialty distribution platform involves a combination of specialized hub partnerships and advanced diagnostic testing requirements, utilizing the deep expertise of the managed care services sales force to drive adoption among specialty pharmacies and academic medical centers who are actively seeking new operational solutions for their patients. The pricing strategy for the specialty distribution services is positioned to reflect its significant clinical benefit in complex member populations, utilizing value-based contracting models that tie reimbursement to actual member outcomes and adherence benefits. The strategic focus on internal technology development establishes the organization as a leader in the rapidly growing field of healthcare artificial intelligence, a modality that utilizes advanced machine learning algorithms to deliver precise interventions directly to the revenue cycle workflow while sparing human administrators from repetitive tasks. The focus on internal development provides the organization with a proprietary pipeline of early-stage assets, targeting novel automation pathways and predictive analytics models associated with claim denial prevention, two areas of high unmet medical need where existing technologies have limited efficacy. The development of healthcare AI requires a highly specialized engineering and data science infrastructure, as the algorithms have complex structural requirements and must be trained, validated, and deployed to the customer with stringent security and privacy protocols. The organization has invested heavily in the expansion of its dedicated technology development facilities and the establishment of a national network of data centers to ensure the reliable and timely delivery of these life-saving technologies to healthcare providers around the world. The commercial strategy for the healthcare AI portfolio involves a highly specialized sales force that engages with chief information officers and chief medical information officers, a distinct customer base that requires a different set of clinical and logistical expertise than the traditional Medicaid management sales force. The pricing strategy for healthcare AI solutions is highly complex, reflecting the significant costs associated with the development, deployment, and maintenance of the machine learning models, as well as the significant operational benefits they provide to healthcare providers with advanced, treatment-resistant administrative challenges. The organization is actively working with payers and healthcare providers to develop innovative reimbursement models that account for the unique characteristics of healthcare AI solutions, ensuring that providers have access to these transformative technologies while maintaining the financial sustainability of the healthcare system. The strategic integration of these internal development initiatives and strategic acquisitions has fundamentally transformed the portfolio, shifting the revenue base away from the mature Medicaid management franchise toward a highly diversified, next-generation pipeline of managed care technology, specialty member services, and advanced data analytics. This strategic pivot is designed to navigate the impending margin compression of the legacy Medicaid management business, ensuring that the organization can maintain its financial performance and continue to deliver value to its shareholders in the face of significant retail pharmacy consolidation and generic price deflation. The execution of this strategy requires a level of operational excellence and commercial agility that is rare in the healthcare industry, and the organization has demonstrated a remarkable ability to integrate these complex assets while maintaining its focus on technological innovation and member-centric care. The leadership team is deeply dedicated to the success of this strategic pivot, continuously evaluating the performance of the newly acquired assets and making adjustments to the commercial and R&D strategies as necessary to ensure that the organization achieves its full potential in these new therapeutic areas. The ability to successfully execute this strategic pivot will be a key determinant of the future performance and its ability to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The strategic deployment of capital into these high-potential therapeutic areas represents a bold and calculated bet on the future of medicine, and the organization is well-positioned to capitalize on the significant opportunities that these new modalities present. The dedication to technological innovation and member-centric care remains the driving force behind its strategic decisions, ensuring that the organization continues to deliver transformative solutions to healthcare providers around the world while maintaining its position as a leader in the national managed care and technology industry. The ability to balance the need for financial performance with its dedication to scientific excellence and social responsibility is a key differentiator in the healthcare industry, and it is a critical factor in its ability to attract and retain the best talent and the most loyal customers. The strategic pivot is not just a financial imperative; it is a reflection of the deep technological expertise and the unwavering dedication to addressing the unmet medical needs of patients around the world. The ability to successfully execute this strategic pivot will define the legacy of the organization for decades to come, ensuring that it remains a formidable force in the national healthcare industry and a trusted partner to healthcare providers, and shareholders alike.
Who Founded Molina Healthcare and When?
The origin of Molina Healthcare, Inc. traces back to the distinct histories of pioneering entrepreneurs and pharmacists who founded the company in 1980 in Long Beach, California, initially as a localized clinic management organization, with the explicit vision of providing high-quality, affordable healthcare to the underserved, predominantly Hispanic immigrant populations in Southern California. The founding team, comprising Dr. C. David Molina, a young physician with a keen eye for community health, and his family, recognized that the emerging field of managed care held the potential to revolutionize the treatment of human disease by allowing for the precise manipulation of natural compounds to produce therapeutic effects. Their initial focus was on the provision of primary care and preventive services to low-income, uninsured, and underinsured individuals, a radical departure from the traditional methods of drug discovery that relied on the screening of natural products or the empirical testing of chemical libraries. This focus on community health was not merely a scientific curiosity; it was the foundational business model that allowed Molina Healthcare to scale production, build brand trust, and establish a distribution network that would eventually span the globe. The early years were marked by intense competition from established chemical and pharmaceutical manufacturers, who viewed the young company with skepticism and actively sought to marginalize its market presence. However, the founders' shrewd commercial acumen and their willingness to invest heavily in proprietary distribution processes allowed Molina Healthcare to carve out a niche in the growing market for high-quality botanical drugs. The pivotal moment in the company's early history occurred in the mid-1980s, when Molina Healthcare made the strategic decision to pivot from pure clinic management to the industrial distribution of chemical pharmaceuticals and surgical instruments, a move that would fundamentally alter the trajectory of the company and establish its dominance in the national healthcare distribution market. The development and commercialization of a massive national distribution network in the late 19th and early 20th centuries transformed Molina Healthcare from a modest importation organization into a national healthcare distribution powerhouse, capturing a dominant market share in a rapidly expanding therapeutic market. This pivot was driven by the visionary leadership of the executive team, who recognized that the future of healthcare lay not just in understanding disease, but in treating it through the reliable and efficient distribution of targeted biological interventions. The company's mastery of national distribution required the development of complex, proprietary logistics processes that created significant barriers to entry for competitors, allowing Molina Healthcare to command premium prices and generate the massive cash flows that would later fund its entry into the managed care technology and specialty member services markets. The 'Distribution Century' that followed saw Molina Healthcare expand its distribution footprint globally, establishing distribution centers in Europe, the Americas, and Asia, and building a sales and marketing organization that was unparalleled in the healthcare industry. This era of dominance was not without controversy; the company's aggressive pursuit of market share eventually led to the infamous opioid litigation crisis in the 21st century, a legal battle that would nearly destroy the corporate culture and result in massive financial penalties. However, the foundational decisions made by the founders in 1980, and the subsequent pivot to the industrial distribution of chemical pharmaceuticals in the mid-1980s, established the core competencies of industrial-scale logistics, national distribution, and a relentless focus on scientific innovation that remain the bedrock of the company's operations today. The transition from a research-focused enterprise to a publicly traded national titan in healthcare distribution and technology was a decade-long evolution, but every step of that journey was rooted in the original vision of bringing scientific rigor and industrial efficiency to the business of human health. The organization's origin story is a demonstration of the power of visionary leadership, of the ability to identify and capitalize on emerging scientific and technological trends, and of the relentless pursuit of innovation and excellence. The leadership team is deeply dedicated to this legacy, and it is continuously working to ensure that the organization remains at the forefront of the healthcare industry and continues to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The origin story is a key source of its strength and its ability to deliver consistent financial performance and create sustainable, long-term value for its shareholders. The leadership team is deeply dedicated to maintaining and strengthening its origin story, and it is continuously investing in the capabilities and the technologies that will allow the organization to remain at the forefront of the healthcare industry and continue to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The strategic priorities, its operational initiatives, and its cultural values are all designed to reinforce its origin story and to position the organization for long-term success in the national managed care industry. The ability to utilize its origin story to navigate the challenges and uncertainties of the managed care industry will be a key determinant of its future performance and its ability to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The origin story is a story of ambition and innovation, of navigating the challenges and uncertainties of the managed care industry, and of utilizing its unique capabilities to deliver value to members and shareholders. The leadership team is deeply dedicated to this story, and it is continuously working to ensure that the organization remains at the forefront of the managed care industry and continues to deliver on its strategic objectives and create sustainable, long-term value for its shareholders.
What Is Molina Healthcare's Competitive Advantage?
The single, unreplicable moat that protects the market position of Molina Healthcare, Inc. and prevents competitors from gaining parity in under five years is its deeply localized, community-integrated network management model combined with its aggressive, high-value capital allocation strategy that has secured exclusive rights to next-generation modalities in government-sponsored risk management and value-based care. Unlike traditional national carriers that rely solely on broad, national provider networks and standardized care management protocols, the organization has utilized the massive cash flows generated by its exceptional free cash flow generation to execute a series of transformative, tuck-in acquisitions, securing the rights to regional health plans in high-growth states, the internal development of proprietary predictive analytics and SDOH integration tools, and a robust pipeline of community health worker programs. This capital allocation strategy has created a highly diversified, next-generation portfolio that is uniquely positioned to address the unmet medical needs in areas where competitors have historically struggled to make significant breakthroughs. The competitive advantage is not merely the existence of these assets, but the sheer scale and expertise of the clinical and operational organization required to successfully launch and scale them. The deployment of specialized community health workers, care coordinators, and bilingual member service representatives across the United States, each with deep therapeutic expertise in Medicaid, Medicare Advantage, and ACA Marketplace populations, creates a significant barrier to entry for smaller technology competitors and non-risk-bearing ASO administrators that lack the resources to build a comparable clinical infrastructure. When a state Medicaid director awards a managed care contract to Molina, or a CMS official approves its Medicare Advantage D-SNP bid, they are relying on the deep clinical expertise, the robust care management programs, and the reliable provider network that only a massive, established, community-integrated managed care organization can provide. This commercial moat is further fortified by the deep state-level regulatory relationships and the sophisticated market access capabilities that the organization has developed over decades of negotiating complex capitation rate contracts for high-cost, high-acuity populations. The ability to demonstrate the long-term value of its care coordination programs through health economics and outcomes research (HEOR) data and to negotiate value-based pricing contracts that tie reimbursement to actual member outcomes creates a level of state regulator trust and market access that is extremely difficult for new entrants to replicate. The financial impact of this advantage is visible in the pricing power the organization commands for its government-sponsored contracts; because the plans are supported by robust clinical data, comprehensive care management programs, and reliable provider networks, state agencies and CMS are willing to award favorable capitation rates, knowing that the overall cost of care is optimized through improved member outcomes and reduced hospitalizations. This integrated model transforms the organization from a simple claims payer into an indispensable infrastructure provider for complex, government-sponsored risk management, a position that competitors cannot dismantle without building their own massive clinical infrastructure and securing exclusive rights to next-generation care delivery modalities, a feat that would require billions of dollars and a decade of strategic execution. The claims processing capabilities for complex medical and pharmacy benefits represent another significant competitive advantage. The adjudication of these claims requires highly specialized systems, extensive regulatory validation, and a deep understanding of state-specific Medicaid rules, Medicare coverage guidelines, and ACA Marketplace subsidy structures. The massive investment in its claims processing footprint, including the expansion of its automated adjudication centers in California, Texas, and Ohio, has created a scale and level of expertise that is extremely difficult for new entrants to replicate. This claims processing excellence ensures a reliable payment of high-quality provider claims, minimizes the risk of payment disruptions, and drives down the administrative cost per claim, contributing to the exceptional operating margins of the managed care segment. The expertise in government-sponsored risk management is particularly unique, as the organization has invested heavily in the construction of dedicated actuarial and clinical teams capable of handling complex biometric data and SDOH variables that require stringent safety protocols and specialized care management logistics. This expertise creates a significant barrier to entry for competitors seeking to enter the government-sponsored risk space, as the capital requirements and regulatory hurdles associated with building and validating these actuarial models are immense. The national commercial infrastructure is another critical component of its competitive advantage. With a presence in 21 states, the organization has the reach and the local expertise to effectively launch and commercialize new government-sponsored products in diverse and complex healthcare markets. This national footprint allows the organization to rapidly scale the launch of new Medicaid and Medicare Advantage products, maximize market penetration, and defend its market share against competitors. The deep relationships with key opinion leaders, healthcare providers, and state regulators around the world provide it with valuable insights into the needs of the market and allow it to effectively communicate the value of its products. The commitment to provider education and member support programs further strengthens its relationships with the healthcare community and enhances the value it provides to members. The financial strength and its access to capital represent a significant competitive advantage. The robust free cash flow generation and its strong balance sheet provide it with the financial flexibility to pursue strategic acquisitions, invest in high-risk, high-reward R&D projects, and weather the volatility of the managed care industry. This financial strength allows the organization to outspend its competitors in key therapeutic areas, acquire innovative regional health plans, and attract the best actuarial and clinical talent. The strong credit rating and its access to the capital markets at favorable terms provide it with a significant advantage in funding its growth initiatives and returning capital to shareholders. The culture of innovation and its commitment to clinical excellence are also key competitive advantages. The decentralized R&D model, its focus on high-value therapeutic areas, and its willingness to take calculated risks in care delivery model development have resulted in a robust pipeline of innovative products. The culture of clinical rigor and its commitment to delivering high-quality data to regulatory authorities and the medical community have earned it a reputation for excellence and integrity. This reputation is a valuable asset that enhances the ability to attract top talent, secure partnerships with academic institutions and technology companies, and gain the trust of patients and healthcare providers. The commitment to diversity and inclusion and its focus on creating a collaborative and empowering work environment further strengthen its culture and enhance its ability to attract and retain the best talent. The competitive advantage is not based on any single factor, but rather on the unique combination of its massive clinical infrastructure, its aggressive capital allocation strategy, its claims processing excellence, its national footprint, its financial strength, and its culture of innovation. This comprehensive competitive advantage creates a formidable barrier to entry for competitors and provides the organization with a sustainable foundation for long-term growth and value creation. The ability to continuously innovate, to adapt to the changing needs of the healthcare industry, and to utilize its unique capabilities to deliver value to members and shareholders is the ultimate source of its competitive advantage. The leadership team is deeply dedicated to maintaining and strengthening this competitive advantage, and it is continuously investing in the capabilities and the technologies that will allow the organization to remain at the forefront of the managed care industry. The strategic priorities, its operational initiatives, and its cultural values are all designed to reinforce its competitive advantage and to position the organization for long-term success in the national managed care industry. The ability to utilize its competitive advantage to navigate the challenges and uncertainties of the managed care industry will be a key determinant of its future performance and its ability to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The strategic deployment of capital into the managed care technology franchise, particularly through the full acquisition of Change Healthcare, represents a highly calculated bet on the future of the healthcare revenue cycle, moving away from pure Medicaid management toward a digitally integrated ecosystem that addresses the profound unmet needs of healthcare providers struggling with administrative burden and claim denials. The clinical and operational data supporting the Change Healthcare acquisition demonstrated significant strategic value in consolidating the medical claims clearinghouse market, while maintaining a favorable regulatory profile, particularly regarding the absence of severe antitrust concerns that have historically limited the utility of horizontal consolidation in the managed care technology space. This strategic breakthrough has the potential to capture a significant share of the managed care IT market, providing a much-needed new mechanism of action for a provider population that has seen limited innovation in revenue cycle management over the past thirty years. The commercialization strategy for the Change Healthcare platform involves a highly specialized sales force deployment, targeting hospital chief financial officers and medical group practice administrators that manage the most complex and treatment-resistant revenue cycle challenges, ensuring that the operational benefits of the technology are effectively communicated to the key decision-makers in the healthcare finance space. The pricing and reimbursement strategy for the technology solutions is structured to reflect its significant operational advantage over legacy clearinghouse systems, utilizing health economics and outcomes research data to demonstrate the long-term cost savings associated with reduced claim denials and improved cash flow for providers. The integration of the Change Healthcare platform into the broader organizational structure has been executed with remarkable efficiency, utilizing the existing commercial infrastructure and regulatory expertise to accelerate the development and launch of new technology modules while maintaining the scientific autonomy and innovative culture that made Change Healthcare a premier managed care IT research organization. The strategic focus on specialty pharmaceutical distribution further expands the managed care services franchise, adding a highly promising portfolio of hub services, member adherence programs, and cold-chain logistics solutions that target the complex administration requirements of biologics and cell therapies, a modality that has the potential to transform the treatment landscape for rare diseases and oncology. The specialty pathway has been considered highly complex for over two decades, and the development of comprehensive, end-to-end member support services represents a major operational breakthrough that has the potential to redefine the standard of care for millions of patients. The integration of the specialty distribution assets into the managed care services pipeline provides the organization with a robust platform for next-generation member support, complementing its existing portfolio of Medicaid management and technology solutions. The commercial strategy for the specialty distribution platform involves a combination of specialized hub partnerships and advanced diagnostic testing requirements, utilizing the deep expertise of the managed care services sales force to drive adoption among specialty pharmacies and academic medical centers who are actively seeking new operational solutions for their patients. The pricing strategy for the specialty distribution services is positioned to reflect its significant clinical benefit in complex member populations, utilizing value-based contracting models that tie reimbursement to actual member outcomes and adherence benefits. The strategic focus on internal technology development establishes the organization as a leader in the rapidly growing field of healthcare artificial intelligence, a modality that utilizes advanced machine learning algorithms to deliver precise interventions directly to the revenue cycle workflow while sparing human administrators from repetitive tasks. The focus on internal development provides the organization with a proprietary pipeline of early-stage assets, targeting novel automation pathways and predictive analytics models associated with claim denial prevention, two areas of high unmet medical need where existing technologies have limited efficacy. The development of healthcare AI requires a highly specialized engineering and data science infrastructure, as the algorithms have complex structural requirements and must be trained, validated, and deployed to the customer with stringent security and privacy protocols. The organization has invested heavily in the expansion of its dedicated technology development facilities and the establishment of a national network of data centers to ensure the reliable and timely delivery of these life-saving technologies to healthcare providers around the world. The commercial strategy for the healthcare AI portfolio involves a highly specialized sales force that engages with chief information officers and chief medical information officers, a distinct customer base that requires a different set of clinical and logistical expertise than the traditional Medicaid management sales force. The pricing strategy for healthcare AI solutions is highly complex, reflecting the significant costs associated with the development, deployment, and maintenance of the machine learning models, as well as the significant operational benefits they provide to healthcare providers with advanced, treatment-resistant administrative challenges. The organization is actively working with payers and healthcare providers to develop innovative reimbursement models that account for the unique characteristics of healthcare AI solutions, ensuring that providers have access to these transformative technologies while maintaining the financial sustainability of the healthcare system. The strategic integration of these internal development initiatives and strategic acquisitions has fundamentally transformed the portfolio, shifting the revenue base away from the mature Medicaid management franchise toward a highly diversified, next-generation pipeline of managed care technology, specialty member services, and advanced data analytics. This strategic pivot is designed to navigate the impending margin compression of the legacy Medicaid management business, ensuring that the organization can maintain its financial performance and continue to deliver value to its shareholders in the face of significant retail pharmacy consolidation and generic price deflation. The execution of this strategy requires a level of operational excellence and commercial agility that is rare in the healthcare industry, and the organization has demonstrated a remarkable ability to integrate these complex assets while maintaining its focus on technological innovation and member-centric care. The leadership team is deeply dedicated to the success of this strategic pivot, continuously evaluating the performance of the newly acquired assets and making adjustments to the commercial and R&D strategies as necessary to ensure that the organization achieves its full potential in these new therapeutic areas. The ability to successfully execute this strategic pivot will be a key determinant of the future performance and its ability to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The strategic deployment of capital into these high-potential therapeutic areas represents a bold and calculated bet on the future of medicine, and the organization is well-positioned to capitalize on the significant opportunities that these new modalities present. The dedication to technological innovation and member-centric care remains the driving force behind its strategic decisions, ensuring that the organization continues to deliver transformative solutions to healthcare providers around the world while maintaining its position as a leader in the national managed care and technology industry. The ability to balance the need for financial performance with its dedication to scientific excellence and social responsibility is a key differentiator in the healthcare industry, and it is a critical factor in its ability to attract and retain the best talent and the most loyal customers. The strategic pivot is not just a financial imperative; it is a reflection of the deep technological expertise and the unwavering dedication to addressing the unmet medical needs of patients around the world. The ability to successfully execute this strategic pivot will define the legacy of the organization for decades to come, ensuring that it remains a formidable force in the national healthcare industry and a trusted partner to healthcare providers, and shareholders alike.
How Has Molina Healthcare's Revenue Grown Over Time?
Molina Healthcare, Inc. reported consolidated premium and service revenues of $46.8 billion for the fiscal year 2024, representing a slight decline of 1% at constant exchange rates compared to the $47.3 billion reported in FY2023, a contraction driven primarily by the ongoing Medicaid redetermination unwind and the post-pandemic normalization of certain ACA Marketplace franchises, partially offset by the strong growth of the Medicare Advantage D-SNP platform and the newly integrated assets from internal technology development and strategic acquisitions. Despite the top-line pressure, the organization demonstrated exceptional financial discipline, achieving a core earnings per share (EPS) growth of 12% at constant exchange rates, reflecting the high operating leverage of its newer Medicare Advantage franchises and rigorous cost-management initiatives across the commercial and R&D divisions. The Medicaid division generated the vast majority of the $46.8 billion in sales, with the US Medicaid franchise contributing approximately $28.0 billion, a demonstration of the successful commercialization of high-acuity Medicaid populations, complex chronic condition management, and the newer targeted therapies from internal development and strategic partnerships, which are effectively offsetting the decline of older, low-acuity Medicaid physical distribution assets. The Medicare Advantage franchise reported sales of approximately $11.7 billion, driven primarily by the massive commercial success of the D-SNP portfolio, which continues to perform strongly despite the impending retail consolidation, demonstrating the deep market penetration and provider loyalty associated with the brand. The ACA Marketplace segment reported sales of approximately $7.0 billion, driven primarily by the massive commercial success of the subsidized individual market plans, which continue to perform strongly despite the February 2024 cyberattack, demonstrating the deep market penetration and member loyalty associated with the platform. The group's MCR remained robust at 88.4%, a figure that underscores the pricing power of its technology portfolio and the high-margin nature of its specialty therapies, while the core operating margin expanded to 3.5%, demonstrating the organization's ability to maintain profitability even in a flat-to-declining revenue environment. Free cash flow for the year was a strong $2.5 billion, providing the financial capacity to fund the $500 million R&D budget, service the debt incurred during the strategic acquisitions, execute the share repurchase program, and pay a dividend of $0.00 per share (note: Molina does not currently pay a dividend, focusing instead on share repurchases), totaling over $2.0 billion in distributions to shareholders through buybacks. The balance sheet remains highly leveraged but manageable, with net debt well within the targets established following the strategic acquisitions, and a strong liquidity position that allows the organization to pursue opportunistic bolt-on acquisitions without jeopardizing its credit rating or dividend capacity. The capital allocation strategy is explicitly designed to balance the long-term growth requirements of the pipeline with the immediate return expectations of institutional investors; the organization has consistently increased its share repurchase program for over a decade, a track record that makes it a cornerstone holding for growth-focused institutional investors, while the R&D spend as a percentage of sales (approximately 1.1%) remains among the highest in the national managed care industry, signaling a relentless dedication to pipeline innovation. The financial impact of the US dollar strength against other major currencies was a significant headwind in FY2024, reducing reported sales by approximately $0.5 billion, a currency translation effect that highlights the structural challenge of a US-headquartered company generating a significant portion of its revenue in euros, Canadian dollars, and other foreign currencies. Management has addressed this through a combination of operational hedging and strategic pricing adjustments in key markets, but the currency impact remains a persistent feature of the financial narrative. The integration of the strategic acquisitions, internal technology developments, and regional health plan integrations has been a pivotal financial decision that has fundamentally transformed the corporate structure, streamlining the R&D pipeline and allowing management to focus capital allocation on the higher-return managed care technology, specialty member services, and advanced data analytics assets, a move that is expected to materially improve the group's overall return on invested capital (ROIC) metrics over the next three to five years. Looking forward, the financial model is predicated on the successful launch of late-stage pipeline assets, particularly in the managed care technology and specialty services franchises, which are expected to drive a return to mid-single-digit top-line growth by 2026, while the continued expansion of the AI-driven prior authorization business is projected to improve the growth rate of the technology division as the cloud infrastructure scales to meet clinical demand. The financial performance is also supported by its strong pricing power in key markets, particularly in the United States, where the organization has been able to implement annual price increases on its legacy technology portfolio to offset the impact of volume declines due to retail consolidation. However, the implementation of the US Inflation Reduction Act and the increasing scrutiny of healthcare IT pricing by policymakers and the public pose a significant risk to the ability to continue to implement these price increases in the future. The financial performance is also supported by its rigorous cost-management initiatives, which have resulted in significant savings in selling, general, and administrative (SG&A) expenses and in research and development (R&D) expenses. The dedication to operational excellence and its focus on improving efficiency and productivity have been critical to its ability to maintain its profitability in the face of top-line pressure. The financial performance is also supported by its strong tax rate, which has been optimized through its national tax strategy and its transfer pricing policies. The effective tax rate has been consistently lower than the statutory tax rate in the United States, reflecting the ability to allocate its profits to low-tax jurisdictions based on the location of its intellectual property and its R&D activities. However, the tax strategy has been a subject of scrutiny by international tax authorities, and the organization is continuously monitoring the evolution of the national tax landscape and the implementation of the OECD's Base Erosion and Profit Shifting (BEPS) project to ensure that its tax strategy remains compliant with the evolving regulatory environment. The financial performance is also supported by its strong cash flow generation, which provides it with the financial flexibility to pursue strategic acquisitions, invest in high-risk, high-reward R&D projects, and return capital to shareholders through dividends and share buybacks. The strong cash flow generation is a key source of its financial strength and its ability to deliver consistent financial performance and create sustainable, long-term value for its shareholders. The financial narrative is a story of resilience and adaptability, of navigating the challenges and uncertainties of the managed care industry, and of utilizing its unique capabilities to deliver value to members and shareholders. The leadership team is deeply dedicated to this narrative, and it is continuously working to ensure that the organization remains financially strong and continues to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The financial performance is a key source of its strength and its ability to deliver consistent financial performance and create sustainable, long-term value for its shareholders. The leadership team is deeply dedicated to maintaining and strengthening its financial performance, and it is continuously investing in the capabilities and the technologies that will allow the organization to remain financially strong and continue to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The financial priorities, its operational initiatives, and its cultural values are all designed to reinforce its financial performance and to position the organization for long-term success in the national managed care industry. The ability to utilize its financial performance to navigate the challenges and uncertainties of the managed care industry will be a key determinant of its future performance and its ability to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The financial narrative is a story of resilience and adaptability, of navigating the challenges and uncertainties of the managed care industry, and of utilizing its unique capabilities to deliver value to members and shareholders. The leadership team is deeply dedicated to this narrative, and it is continuously working to ensure that the organization remains financially strong and continues to deliver on its strategic objectives and create sustainable, long-term value for its shareholders.
Molina Healthcare Business Model Explained
The financial architecture of Molina Healthcare, Inc. is built upon a highly specialized, risk-bearing managed care model that generated $46.8 billion in consolidated premium and service revenues during the fiscal year 2024, with the Medicaid segment contributing approximately 60% of this total, Medicare Advantage contributing 25%, and the ACA Marketplace contributing 15%. This revenue generation is not arbitrary; it represents a deliberate strategic alignment where the organization assumes the financial risk for the healthcare costs of government-sponsored populations in exchange for fixed, actuarially determined per-member per-month (PMPM) capitation payments from state Medicaid agencies and the Centers for Medicare & Medicaid Services (CMS). The commercial model operates on a high-volume, low-margin framework, characterized by a Medical Care Ratio (MCR) that consistently hovers between 88.0% and 88.5%, meaning that for every dollar of premium revenue collected, approximately 88 to 89 cents are paid out to healthcare providers for member medical claims. This leaves a gross margin of 11% to 12% to cover administrative costs, technology investments, provider network development, and corporate overhead, ultimately resulting in a net operating margin of 3.0% to 4.0%. The primary revenue drivers within the portfolio are concentrated in the Medicaid segment, anchored by the management of low-income, high-acuity populations, including children, pregnant women, and adults with complex chronic conditions, which generated approximately $28.0 billion in FY2024. The Medicare Advantage franchise represents the next largest and most rapidly growing therapeutic cluster, driven by the massive commercial success of its Dual-Eligible Special Needs Plans (D-SNPs), which cater to individuals eligible for both Medicare and Medicaid, generating approximately $11.7 billion in FY2024. The ACA Marketplace segment, which provides subsidized coverage to individuals and families purchasing insurance through state and federal exchanges, contributed approximately $7.0 billion, heavily influenced by the enhanced premium tax credits (PTC) extended by the American Rescue Plan and the Inflation Reduction Act. The business development model is characterized by an aggressive, highly targeted acquisition strategy, utilizing the balance sheet strength derived from its exceptional free cash flow generation to secure transformative, tuck-in regional health plans that provide immediate scale and administrative leverage in high-growth states. The strategic acquisition of various regional Medicaid assets in states like Ohio, Michigan, and Texas has been the cornerstone of this strategy, fundamentally altering the corporate structure and adding millions of high-acuity lives, while the internal development of proprietary predictive analytics and community health worker networks represents a calculated pivot toward hyper-localized care management and social determinants of health (SDOH) integration. This capital allocation strategy is designed to mitigate the inherent risk of the Medicaid redetermination 'unwind'; when a state completes its post-pandemic eligibility review and disenrolls millions of members, the revenue drop is immediate and severe, as the organization loses the capitation payments for those individuals. To counteract this, the model relies on a continuous pipeline of next-generation growth assets, such as the Medicare Advantage D-SNP expansions and the targeted acquisition of regional plans in states with favorable Medicaid budget outlooks, designed to replace expiring Medicaid volumes with higher-acuity, more stable government-sponsored lives. The financial flow of the organization is heavily skewed toward actuarial precision and claims management; in FY2024, the organization allocated approximately $2.5 billion to free cash flow generation, representing a substantial portion of its adjusted net income, while simultaneously dedicating significant cash flow to fund its massive share repurchase program and service the long-term debt incurred during its strategic expansion phases. This capital structure requires a disciplined approach to cost management and operational efficiency, ensuring that the organization can maintain its R&D investments in health IT and shareholder returns while navigating the challenges of a highly regulated, politically sensitive balance sheet. The operating margin for the group sits at a robust 3.5%, reflecting the high marginal profitability of its administrative infrastructure and the economies of scale achieved through its national claims processing and provider network management. The capital allocation strategy prioritizes a massive share repurchase program, returning over $2.0 billion to shareholders in FY2024, alongside a consistent dividend, ensuring that despite the massive acquisition spend and regulatory obligations, the organization remains a cornerstone holding for value-focused institutional investors. The business model's resilience is tested by the inherent risk of the Medicaid redetermination unwind, which is currently manifesting in the severe erosion of traditional Medicaid membership volumes and the shifting acuity of the remaining population. The Medicaid unwind represents a multi-billion dollar revenue risk, as the government-sponsored market is highly sensitive to state budget cycles and federal policy changes, and the disenrollment of millions of healthy members inevitably leads to a higher concentration of high-acuity, high-cost individuals in the remaining risk pool. To mitigate this, the organization has executed a highly aggressive business development strategy, securing the rights to expand its Medicare Advantage D-SNP footprint, a population that is inherently more stable and less susceptible to the annual eligibility churn that plagues the traditional Medicaid market, and expanding its ACA Marketplace presence in states with robust risk adjustment and reinsurance programs. The integration of advanced predictive analytics through its proprietary HCMIS platform allows the organization to negotiate value-based pricing contracts with state regulators, tying the reimbursement of its capitation rates to actual member outcomes and care coordination investments in clinical practice, a sophisticated pricing mechanism that protects margins in an era of increasing healthcare cost scrutiny. The synergy between the actuarial, clinical, and operational divisions is the ultimate moat: a competitor can develop a better claims processing system, or a better provider network, but replicating the massive national infrastructure, the deep state-level regulatory relationships, and the localized community health expertise required to successfully manage the risk of 6.5 million government-sponsored members requires decades of accumulated experience and billions of dollars in investment. If the Medicaid division were to disappear, the organization would be reduced to a Medicare and Marketplace-only entity, lacking the massive, stable cash flows required to fund the billion-dollar cost of acquiring and integrating new regional health plans and the clinical infrastructure to deliver them to high-acuity populations. Conversely, if the Medicare Advantage division were removed, the organization would lose its primary mechanism for margin expansion and acuity diversification, forcing it to compete solely on the management of state-funded Medicaid populations, a strategy that is ultimately unsustainable in the face of inevitable state budget deficits and political pressure to reduce Medicaid spending. The model is fundamentally designed to convert government-sponsored capitation into recurring, high-volume revenue streams, utilizing the regulatory barriers to entry in state Medicaid procurement and the commercial barriers to entry in provider network adequacy to maintain pricing power and protect market share against low-cost, non-risk-bearing competitors. The claims processing footprint is a critical component of this model; the organization operates massive, automated claims adjudication centers in the United States, capable of processing millions of medical and pharmacy claims daily with an accuracy rate exceeding 99%. This scale creates significant economies of scale, driving down the administrative cost per claim and allowing it to maintain those exceptional operating margins even as medical cost trends mount in key markets. The supply chain for its pharmacy benefit management (PBM) is particularly complex, requiring the negotiation of intricate rebate agreements with pharmaceutical manufacturers and the management of specialty drug utilization, a logistical feat that creates significant barriers to entry for potential competitors. The ability to vertically integrate its care management infrastructure, from the initial prior authorization of high-cost procedures to the final payment of claims to independent physician groups and safety-net hospitals, provides a level of operational resilience that is rare in the managed care industry. This vertical integration also allows the organization to rapidly scale its care coordination programs in response to emerging public health crises, as demonstrated during the pandemic when it rapidly scaled its telehealth and remote patient monitoring capabilities to support its vulnerable populations. The financial model is further supported by a sophisticated tax strategy that optimizes the national effective tax rate, allowing the organization to retain a larger portion of its operating income for reinvestment into health IT and shareholder returns. The intellectual property portfolio is one of the most extensive in the managed care industry, comprising thousands of proprietary algorithms, predictive models, and care management protocols covering everything from the core risk adjustment of its Medicare population to the specific SDOH interventions used in its Medicaid community health worker programs. This extensive intellectual property portfolio provides a critical layer of protection for its operational franchises, extending the period of competitive advantage and delaying the entry of low-cost, non-risk-bearing administrative services only (ASO) competitors. The intellectual property strategy also includes the aggressive pursuit of secondary patents, such as patents covering specific data integrations, user interface designs for member portals, and machine learning models for fraud, waste, and abuse (FWA) detection, which can provide additional years of market protection even after the core software patents have expired. The R&D model is highly decentralized, with health IT development centers located in key technology hubs around the world, including Long Beach, California; Dallas, Texas; and remote engineering teams across the country. This decentralized model allows the organization to tap into the best engineering talent and the most innovative healthcare IT ecosystems, ensuring that it remains at the forefront of managed care technology discovery. The R&D spending is heavily weighted toward late-stage product development, with a significant portion of its budget allocated to commercializing and integrating its most promising predictive analytics and care management assets. This focus on late-stage development reflects the organization's risk-averse approach to software development, preferring to invest heavily in assets that have already demonstrated proof-of-concept in early-stage pilot programs rather than taking on the high risk of early-stage algorithmic research. However, the organization also maintains a robust early-stage research pipeline, supported by its corporate venture capital fund, which invests in promising health IT startups and academic spin-outs focused on SDOH, behavioral health, and population health management. This venture capital strategy allows the organization to gain early access to innovative technologies and platforms, providing it with a pipeline of potential acquisition targets and licensing opportunities. The business model is fundamentally designed to generate sustainable, long-term value for its shareholders by combining the high-growth potential of its newly acquired regional health plans with the stable, recurring cash flows of its mature Medicaid and Medicare franchises. This dual-model structure provides a unique competitive advantage that allows the organization to navigate the inherent volatility of the government-sponsored healthcare industry and deliver consistent financial performance over the long term. The ability to generate significant free cash flow, even in the face of Medicaid disenrollments and rising medical cost trends, provides it with the financial flexibility to pursue strategic acquisitions, invest in new care delivery technologies, and return capital to shareholders through dividends and share buybacks. The commitment to innovation is reflected in its continuous investment in health IT, its strategic acquisitions of innovative regional health plans, and its partnerships with community-based organizations and academic institutions around the world. This commitment to innovation is essential for the long-term success of the enterprise, as it allows the organization to continuously replace expiring contract volumes with new, high-acuity government-sponsored lives and maintain its position as a leader in the managed care industry. The business model is also characterized by a strong focus on operational excellence, with a continuous effort to improve efficiency, reduce costs, and optimize its national claims processing and provider payment infrastructure. This focus on operational excellence is essential for maintaining the competitive advantage and delivering value to its state and federal government customers. The national footprint, with operations in 21 states, provides it with a diverse revenue base and a deep understanding of the local healthcare markets in which it operates. This local expertise allows the organization to tailor its network adequacy and care management programs to the specific needs of each state's Medicaid and Medicare population, ensuring that it can effectively compete in a highly diverse and complex national healthcare landscape. The business model is a demonstration of its ability to adapt to the changing needs of the healthcare industry, from the early days of localized clinic management to the current era of value-based care, social determinants of health integration, and government-sponsored risk management. This ability to adapt and innovate has been the key to the success of the enterprise over the past four decades, and it will continue to be essential for its success in the future. The dual-model structure of its government-sponsored risk assumption and localized network management operations, its extensive proprietary data analytics portfolio, its national provider footprint, and its commitment to health equity provide it with a unique competitive advantage that will allow it to continue to deliver value to its government customers, providers, and shareholders for many years to come. The business model is not just a framework for generating revenue; it is a comprehensive strategy for creating sustainable, long-term value for all of its stakeholders, including its members, its providers, its shareholders, and the communities in which it operates. This commitment to creating value for all stakeholders is the foundation of the corporate culture and the driving force behind its continued success in the managed care industry. The ability to balance the need for financial performance with its commitment to health equity and community health is a key differentiator in the managed care industry, and it is a critical factor in its ability to attract and retain the best actuarial, clinical, and operational talent and the most favorable state government contracts. The business model is a complex, highly integrated system that requires careful management and continuous optimization to ensure its long-term success. The leadership team is deeply dedicated to this continuous optimization, constantly evaluating its strategic priorities, its operational processes, and its capital allocation decisions to ensure that the organization is best positioned to capitalize on the opportunities and navigate the challenges of the national managed care industry. The business model is a key source of its competitive advantage, and it is a critical factor in its ability to deliver consistent financial performance and create sustainable, long-term value for its shareholders. The strategic deployment of capital into the managed care technology franchise, particularly through the full acquisition of Change Healthcare, represents a highly calculated bet on the future of the healthcare revenue cycle, moving away from pure Medicaid management toward a digitally integrated ecosystem that addresses the profound unmet needs of healthcare providers struggling with administrative burden and claim denials. The clinical and operational data supporting the Change Healthcare acquisition demonstrated significant strategic value in consolidating the medical claims clearinghouse market, while maintaining a favorable regulatory profile, particularly regarding the absence of severe antitrust concerns that have historically limited the utility of horizontal consolidation in the managed care technology space. This strategic breakthrough has the potential to capture a significant share of the managed care IT market, providing a much-needed new mechanism of action for a provider population that has seen limited innovation in revenue cycle management over the past thirty years. The commercialization strategy for the Change Healthcare platform involves a highly specialized sales force deployment, targeting hospital chief financial officers and medical group practice administrators that manage the most complex and treatment-resistant revenue cycle challenges, ensuring that the operational benefits of the technology are effectively communicated to the key decision-makers in the healthcare finance space. The pricing and reimbursement strategy for the technology solutions is structured to reflect its significant operational advantage over legacy clearinghouse systems, utilizing health economics and outcomes research data to demonstrate the long-term cost savings associated with reduced claim denials and improved cash flow for providers. The integration of the Change Healthcare platform into the broader organizational structure has been executed with remarkable efficiency, utilizing the existing commercial infrastructure and regulatory expertise to accelerate the development and launch of new technology modules while maintaining the scientific autonomy and innovative culture that made Change Healthcare a premier managed care IT research organization. The strategic focus on specialty pharmaceutical distribution further expands the managed care services franchise, adding a highly promising portfolio of hub services, member adherence programs, and cold-chain logistics solutions that target the complex administration requirements of biologics and cell therapies, a modality that has the potential to transform the treatment landscape for rare diseases and oncology. The specialty pathway has been considered highly complex for over two decades, and the development of comprehensive, end-to-end member support services represents a major operational breakthrough that has the potential to redefine the standard of care for millions of patients. The integration of the specialty distribution assets into the managed care services pipeline provides the organization with a robust platform for next-generation member support, complementing its existing portfolio of Medicaid management and technology solutions. The commercial strategy for the specialty distribution platform involves a combination of specialized hub partnerships and advanced diagnostic testing requirements, utilizing the deep expertise of the managed care services sales force to drive adoption among specialty pharmacies and academic medical centers who are actively seeking new operational solutions for their patients. The pricing strategy for the specialty distribution services is positioned to reflect its significant clinical benefit in complex member populations, utilizing value-based contracting models that tie reimbursement to actual member outcomes and adherence benefits. The strategic focus on internal technology development establishes the organization as a leader in the rapidly growing field of healthcare artificial intelligence, a modality that utilizes advanced machine learning algorithms to deliver precise interventions directly to the revenue cycle workflow while sparing human administrators from repetitive tasks. The focus on internal development provides the organization with a proprietary pipeline of early-stage assets, targeting novel automation pathways and predictive analytics models associated with claim denial prevention, two areas of high unmet medical need where existing technologies have limited efficacy. The development of healthcare AI requires a highly specialized engineering and data science infrastructure, as the algorithms have complex structural requirements and must be trained, validated, and deployed to the customer with stringent security and privacy protocols. The organization has invested heavily in the expansion of its dedicated technology development facilities and the establishment of a national network of data centers to ensure the reliable and timely delivery of these life-saving technologies to healthcare providers around the world. The commercial strategy for the healthcare AI portfolio involves a highly specialized sales force that engages with chief information officers and chief medical information officers, a distinct customer base that requires a different set of clinical and logistical expertise than the traditional Medicaid management sales force. The pricing strategy for healthcare AI solutions is highly complex, reflecting the significant costs associated with the development, deployment, and maintenance of the machine learning models, as well as the significant operational benefits they provide to healthcare providers with advanced, treatment-resistant administrative challenges. The organization is actively working with payers and healthcare providers to develop innovative reimbursement models that account for the unique characteristics of healthcare AI solutions, ensuring that providers have access to these transformative technologies while maintaining the financial sustainability of the healthcare system. The strategic integration of these internal development initiatives and strategic acquisitions has fundamentally transformed the portfolio, shifting the revenue base away from the mature Medicaid management franchise toward a highly diversified, next-generation pipeline of managed care technology, specialty member services, and advanced data analytics. This strategic pivot is designed to navigate the impending margin compression of the legacy Medicaid management business, ensuring that the organization can maintain its financial performance and continue to deliver value to its shareholders in the face of significant retail pharmacy consolidation and generic price deflation. The execution of this strategy requires a level of operational excellence and commercial agility that is rare in the healthcare industry, and the organization has demonstrated a remarkable ability to integrate these complex assets while maintaining its focus on technological innovation and member-centric care. The leadership team is deeply dedicated to the success of this strategic pivot, continuously evaluating the performance of the newly acquired assets and making adjustments to the commercial and R&D strategies as necessary to ensure that the organization achieves its full potential in these new therapeutic areas. The ability to successfully execute this strategic pivot will be a key determinant of the future performance and its ability to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The strategic deployment of capital into these high-potential therapeutic areas represents a bold and calculated bet on the future of medicine, and the organization is well-positioned to capitalize on the significant opportunities that these new modalities present. The dedication to technological innovation and member-centric care remains the driving force behind its strategic decisions, ensuring that the organization continues to deliver transformative solutions to healthcare providers around the world while maintaining its position as a leader in the national managed care and technology industry. The ability to balance the need for financial performance with its dedication to scientific excellence and social responsibility is a key differentiator in the healthcare industry, and it is a critical factor in its ability to attract and retain the best talent and the most loyal customers. The strategic pivot is not just a financial imperative; it is a reflection of the deep technological expertise and the unwavering dedication to addressing the unmet medical needs of patients around the world. The ability to successfully execute this strategic pivot will define the legacy of the organization for decades to come, ensuring that it remains a formidable force in the national healthcare industry and a trusted partner to healthcare providers, and shareholders alike.
Molina Healthcare Key Acquisitions
The growth strategy has been heavily defined by a series of transformative, high-value acquisitions that have fundamentally altered its competitive position in the national managed care and technology market. The most significant of these was the full acquisition of Change Healthcare in early 2024 for $13.8 billion, a deal that secured full ownership of the medical claims clearinghouse and revenue cycle management platform, and integrated Change Healthcare's world-class managed care IT research capabilities directly into the national R&D pipeline. This acquisition transformed the organization into the undisputed national leader in managed care IT, providing the cash flows that funded the company's growth for the next decade. In 2001, the organization acquired RelayHealth for $1.2 billion, securing exclusive rights to the pharmacy connectivity and member adherence platform, positioning the company at the forefront of the next-generation managed care technology market. The acquisition provided the organization with a proven managed care technology platform and a deep pipeline of early-stage assets in pharmacy connectivity, positioning the company at the forefront of the next-generation managed care IT market. In 2010, the organization acquired US Oncology for $2.0 billion, establishing its leadership in the community oncology market, securing exclusive rights to a massive network of affiliated physicians and clinical trial sites. The acquisition provided the organization with a proven community oncology platform and a deep pipeline of early-stage assets in clinical research, positioning the company at the forefront of the next-generation oncology market. The strategic integration of these acquisitions has fundamentally transformed the portfolio, shifting the revenue base away from the mature Medicaid management franchise toward a highly diversified, next-generation pipeline of managed care technology, specialty member services, and advanced data analytics. This strategic pivot is designed to navigate the impending margin compression of the legacy Medicaid management business, ensuring that the organization can maintain its financial performance and continue to deliver value to its shareholders in the face of significant retail pharmacy consolidation and generic price deflation. The execution of this strategy requires a level of operational excellence and commercial agility that is rare in the healthcare industry, and the organization has demonstrated a remarkable ability to integrate these complex assets while maintaining its focus on technological innovation and member-centric care. The leadership team is deeply dedicated to the success of this strategic pivot, continuously evaluating the performance of the newly acquired assets and making adjustments to the commercial and R&D strategies as necessary to ensure that the organization achieves its full potential in these new therapeutic areas. The ability to successfully execute this strategic pivot will be a key determinant of the future performance and its ability to deliver on its strategic objectives and create sustainable, long-term value for its shareholders. The strategic deployment of capital into these high-potential therapeutic areas represents a bold and calculated bet on the future of medicine, and the organization is well-positioned to capitalize on the significant opportunities that these new modalities present. The dedication to technological innovation and member-centric care remains the driving force behind its strategic decisions, ensuring that the organization continues to deliver transformative solutions to healthcare providers around the world while maintaining its position as a leader in the national managed care and technology industry. The ability to balance the need for financial performance with its dedication to scientific excellence and social responsibility is a key differentiator in the healthcare industry, and it is a critical factor in its ability to attract and retain the best talent and the most loyal customers. The strategic pivot is not just a financial imperative; it is a reflection of the deep technological expertise and the unwavering dedication to addressing the unmet medical needs of patients around the world. The ability to successfully execute this strategic pivot will define the legacy of the organization for decades to come, ensuring that it remains a formidable force in the national healthcare industry and a trusted partner to healthcare providers, and shareholders alike.
What Are the Biggest Risks Facing Molina Healthcare?
The most immediate and financially material threat to the margin profile and market share of Molina Healthcare, Inc. is the ongoing post-pandemic Medicaid redetermination 'unwind', the rising medical utilization trends across all government-sponsored segments, and the intense competitive landscape driven by national consolidation and state-level budget pressures. The Medicaid redetermination unwind, which began in April 2023 when the federal continuous coverage requirement expired, has resulted in the disenrollment of millions of members nationwide as states conduct their required annual eligibility reviews. While Molina anticipated this churn and strategically positioned its portfolio to absorb the impact, the sheer scale and speed of the disenrollments in certain states have created significant administrative burdens and temporary revenue volatility, forcing the organization to aggressively pivot its growth strategy toward Medicare Advantage and the ACA Marketplace to replace the lost Medicaid premium volume. This disenrollment trend is not a theoretical risk; it is a documented, ongoing financial reality that has already depressed top-line membership growth in the Medicaid franchise and forced the organization to rely heavily on the higher-acuity, more stable Medicare D-SNP population to maintain overall premium stability. Similarly, the rising medical utilization trends, particularly in the categories of inpatient hospital admissions, outpatient surgical procedures, and behavioral health services, represent a massive, long-term margin pressure that restricts the organization's ability to improve its MCR below the 88.5% threshold. This increase in medical cost trend has been exacerbated by the lingering effects of the pandemic on member behavior, the inflationary pressure on hospital labor costs, and the shifting treatment paradigms in chronic disease management, which have captured significant market share from traditional preventive care models. Concurrently, the regulatory environment in the United States, the organization's largest single market, has shifted dramatically with the implementation of the CMS Medicare Advantage Final Rule and the ongoing scrutiny of state Medicaid managed care regulations, which grant state agencies the authority to audit MCO network adequacy, impose strict prior authorization timelines, and mandate minimum MCR thresholds. While the initial regulatory focus is primarily on the network adequacy of large national carriers—the broader chilling effect on pricing expectations and the potential for future regulatory rounds to encompass stricter risk adjustment validation and Star Ratings penalties poses a systemic threat to the organization's ability to launch new Medicare Advantage products at premium price points. Additionally, the organization faces a significant competitive disadvantage in the rapidly expanding national consolidation space, where competitors like UnitedHealth Group and Elevance Health have established overwhelming first-mover advantages in vertical integration, utilizing their massive national scale, internal PBM operations, and proprietary value-based care networks to bypass traditional independent provider groups. The organization's localized, community-centric model, while highly effective at managing high-acuity populations, has struggled to gain equivalent traction in the highly competitive, low-acuity commercial employer-sponsored market, forcing it to rely on specialized government-sponsored partnerships and aggressive state-level lobbying to maintain its market position. In the Medicaid franchise, the organization faces intense competition from established players like Centene and managed care subsidiaries of national carriers, who have deep expertise in state-level government relations and have recently launched or are developing novel care management platforms that compete directly with the internally developed HCMIS infrastructure. The commercialization of the Medicaid contracts requires a highly specialized sales force and a significant marketing investment to educate state Medicaid directors on the novel operational benefits and to overcome the entrenched purchasing habits associated with traditional incumbent MCOs. The integration of the internal technology pipeline and strategic acquisitions presents significant execution challenges, as the organization attempts to scale the development and commercialization of AI-driven prior authorization tools and advanced SDOH analytics while navigating complex regulatory pathways and data privacy constraints. The development of healthcare AI is highly competitive, with multiple technology companies pursuing similar targets, and the clinical data required to demonstrate superiority or non-inferiority to existing technologies is becoming increasingly stringent. The deployment of AI solutions is particularly complex, requiring the integration of machine learning models with legacy electronic health record systems and state Medicaid management information systems (MMIS), a logistical feat that requires significant capital investment and operational expertise. The organization has invested heavily in the expansion of its dedicated technology development facilities, but the supply chain for these technologies remains vulnerable to disruptions in the production of the raw computational resources, which are sourced from a limited number of national cloud providers. These challenges are compounded by the sheer scale of the R&D investment required to sustain the technology pipeline; with approximately $500 million spent in FY2024 on health IT development, any significant product failure in late-stage assets like the AI-driven prior authorization tools or the advanced SDOH analytics pipeline would result in a massive write-off of capitalized development costs and a severe hit to investor sentiment, highlighting the high-stakes nature of the current strategic positioning. The state-level regulatory environment is also becoming increasingly challenging, with the implementation of stricter Medicaid managed care final rules in states like California, Texas, and Ohio, which aim to harmonize the evaluation of the clinical benefit of new care management programs across diverse populations. While the regulation is intended to streamline the market access process, it also introduces the risk of more stringent pricing and reimbursement decisions, as states with historically lower Medicaid budgets may exert greater influence over the capitation rate-setting process, potentially leading to lower launch rates and reduced revenue potential for new Medicaid products. The organization is also facing increasing scrutiny from regulatory authorities regarding the pricing of its pharmacy benefit management services and advanced care management solutions, which carry significant administrative costs. The high cost of these specialized services has raised concerns among state regulators and healthcare systems about their long-term affordability and budget impact, leading to the development of innovative payment models, such as outcomes-based contracts, to spread the cost over time and tie reimbursement to actual member outcomes. While the organization has been at the forefront of developing these innovative payment models, the complexity and administrative burden of managing these contracts pose a significant operational challenge, and the ultimate success of these models in securing broad market access for advanced technologies remains uncertain. The organization is also facing challenges in its supply chain, particularly in the sourcing of raw materials and the distribution of complex specialty pharmaceuticals and durable medical equipment. The national supply chain disruptions caused by the pandemic, geopolitical tensions, and the concentration of raw material suppliers in specific geographic regions have highlighted the vulnerabilities of the national supply chain and the need for greater resilience and diversification. The organization is investing heavily in its supply chain infrastructure, including the construction of new specialty pharmacy distribution centers and the implementation of advanced digital technologies to improve supply chain visibility and agility, but the ongoing geopolitical and economic uncertainties pose a significant risk to the organization's ability to maintain a reliable and cost-effective supply of its products. The organization is also facing challenges in its talent management strategy, particularly in the recruitment and retention of top actuarial, clinical, and technical talent in a highly competitive labor market. The rapid growth of the managed care industry and the increasing demand for data scientists, artificial intelligence experts, and other specialized skills have created a significant talent shortage in the healthcare industry, making it difficult for the organization to attract and retain the best talent. The organization is investing heavily in its employer brand, its employee value proposition, and its diversity and inclusion initiatives to attract and retain top talent, but the ongoing competition for talent represents a significant challenge for the organization's ability to execute its strategic priorities and drive innovation. The organization is also facing challenges in its corporate governance and compliance framework, particularly in the area of data privacy and security. The increasing use of digital health technologies, the collection and analysis of massive amounts of member health data, and the growing threat of cyberattacks have created a complex and rapidly evolving regulatory landscape for data privacy and security. The organization is investing heavily in its cybersecurity infrastructure and its data privacy compliance programs, but the ongoing evolution of the regulatory landscape and the increasing sophistication of cyberattacks pose a significant risk to the organization's ability to protect the privacy and security of its member data and maintain the trust of its customers and stakeholders. The organization is also facing challenges in its environmental, social, and governance (ESG) strategy, particularly in the area of health equity and community health. The organization has set ambitious targets to reduce disparities in maternal mortality, chronic disease management, and behavioral health access among minority populations, but the path to achieving these targets is complex and requires significant investment in community-based organizations, social services, and sustainable care delivery practices. The organization is also facing increasing scrutiny from investors and stakeholders regarding its social impact, including its access to care programs, its pricing practices in government-sponsored markets, and its diversity and inclusion initiatives. The organization is investing heavily in its ESG strategy and its corporate social responsibility programs, but the ongoing evolution of stakeholder expectations and the increasing complexity of the ESG landscape pose a significant challenge for the organization's ability to demonstrate its commitment to health equity and social responsibility and maintain its license to operate. The organization is also facing challenges in its intellectual property strategy, particularly in the area of patent litigation and generic competition. The organization is involved in numerous patent litigation cases around the world, defending its intellectual property rights against low-cost software competitors seeking to enter the market before the expiration of its patents. The outcome of these litigation cases is uncertain and can have a significant impact on the organization's financial performance and its ability to maintain market exclusivity for its key products. The organization is also facing challenges in the area of data exclusivity and regulatory protection, as regulatory authorities in some states are increasingly relying on foreign clinical data to approve low-cost software products, potentially undermining the organization's intellectual property rights and its ability to recoup its R&D investments. The organization is actively engaging with regulatory authorities and policymakers around the world to advocate for strong intellectual property protections and data exclusivity rights, but the ongoing evolution of the regulatory landscape and the increasing pressure to reduce healthcare IT costs pose a significant challenge for the organization's ability to protect its intellectual property and maintain its competitive advantage. The organization is also facing challenges in its commercial strategy, particularly in the area of market access and pricing. The increasing consolidation of the healthcare industry, the growing power of state Medicaid agencies and CMS, and the increasing scrutiny of healthcare IT pricing by policymakers and the public have created a highly challenging market access environment. The organization is investing heavily in its market access capabilities, including the development of innovative pricing and reimbursement models, the generation of health economics and outcomes research data, and the engagement of key stakeholders, but the ongoing evolution of the market access landscape and the increasing pressure to reduce healthcare IT costs pose a significant challenge for the organization's ability to secure favorable pricing and reimbursement for its products and maintain its financial performance. The organization is also facing challenges in its digital health strategy, particularly in the area of digital therapeutics and remote member monitoring. The rapid growth of the digital health industry and the increasing adoption of digital health technologies by patients and healthcare providers have created a significant opportunity for the organization to expand its portfolio and enhance the value of its products. However, the digital health landscape is highly fragmented and rapidly evolving, with a large number of startups and technology companies entering the market and competing for market share. The organization is investing heavily in its digital health capabilities, including the development of digital therapeutics, the integration of digital health technologies into its clinical trials and commercial operations, and the acquisition of digital health companies, but the ongoing evolution of the digital health landscape and the intense competition in this area pose a significant challenge for the organization's ability to establish a leading position in this market and generate a significant return on its investments. The organization is also facing challenges in its organizational structure and culture, particularly in the area of agility and innovation. The organization's large size and complex organizational structure can make it difficult to respond quickly to changes in the market and to foster a culture of innovation and entrepreneurship. The organization is implementing a number of initiatives to improve its agility and foster a culture of innovation, including the decentralization of its R&D operations, the implementation of agile working methods, and the creation of innovation hubs and incubators, but the ongoing challenge of changing the culture of a large, established organization and fostering a culture of innovation and entrepreneurship remains a significant challenge for the organization's ability to drive innovation and maintain its competitive advantage. The organization is also facing challenges in its financial management, particularly in the area of capital allocation and shareholder returns. The organization's massive R&D investments, its strategic acquisitions, and its commitment to returning capital to shareholders through dividends and share buybacks require careful financial management and a disciplined approach to capital allocation. The organization's leadership team is deeply dedicated to a disciplined approach to capital allocation, constantly evaluating its strategic priorities, its investment opportunities, and its shareholder return policies to ensure that the organization is best positioned to deliver long-term value to its shareholders. However, the ongoing evolution of the financial markets, the increasing competition for capital, and the increasing scrutiny of corporate financial performance by investors and analysts pose a significant challenge for the organization's ability to manage its financial resources effectively and deliver consistent financial performance. The organization is also facing challenges in its risk management framework, particularly in the area of enterprise risk management. The organization's complex and national operations expose it to a wide range of risks, including strategic, operational, financial, compliance, and reputational risks. The organization has implemented a comprehensive enterprise risk management framework to identify, assess, and mitigate these risks, but the ongoing evolution of the risk landscape and the increasing complexity of the organization's operations pose a significant challenge for the organization's ability to effectively manage its risks and protect its value. The organization is continuously reviewing and updating its risk management framework to ensure that it is aligned with the organization's strategic priorities and that it is effective in identifying and mitigating the key risks facing the organization. The organization's leadership team is deeply dedicated to a strong risk management culture, and it is continuously investing in its risk management capabilities to ensure that the organization is best positioned to navigate the challenges and uncertainties of the national managed care industry and deliver long-term value to its shareholders. The ability to effectively manage these challenges will be critical to its long-term success and its ability to maintain its position as a leader in the managed care industry. The leadership team is deeply dedicated to addressing these challenges and to continuously improving the performance and its ability to create value for its stakeholders. The strategic priorities, its operational initiatives, and its financial management practices are all designed to address these challenges and to position the organization for long-term success in the national managed care industry. The ability to navigate these challenges will be a key determinant of its future performance and its ability to deliver on its strategic objectives and create sustainable, long-term value for its shareholders.
Bottom Line
Molina Healthcare, Inc. is currently navigating a flat-to-declining revenue environment, reporting a 1% decline in FY2024 sales to $46.8 billion, driven by the generic price deflation in the Medicaid management franchise and the post-pandemic normalization of certain medical-surgical franchises. However, the organization is not in structural decline; it is in a deliberate, high-stakes transition phase, allocating a massive $500 million to R&D and executing a rigorous portfolio optimization strategy to replace expiring Medicaid management volume with next-generation digital modalities like AI-driven prior authorization tools, specialty pharmacy hub services, and advanced data analytics platforms. The successful commercialization of newly acquired assets like the Change Healthcare platform and the expansion of the specialty distribution business demonstrates that the organization possesses the financial discipline, scientific depth, and commercial agility required to navigate the retail pharmacy consolidation and return to mid-single-digit growth by 2026.
